Paclitaxel News and Research RSS Feed - Paclitaxel News and Research

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.
New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA. [More]
NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

NantWorks, Sorrento collaborate to discover and develop novel anti-cancer immunotherapies

NantWorks, Inc. and Sorrento Therapeutics, Inc., announced today that they have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach. [More]
Sanford-Burnham researchers discover control mechanism for glutamine uptake in breast cancer cells

Sanford-Burnham researchers discover control mechanism for glutamine uptake in breast cancer cells

Researchers at Sanford-Burnham Medical Research Institute have discovered a mechanism that explains why some breast cancer tumors respond to specific chemotherapies and others do not. The findings highlight the level of glutamine, an essential nutrient for cancer development, as a determinant of breast cancer response to select anticancer therapies, and identify a marker associated with glutamine uptake, for potential prognosis and stratification of breast cancer therapy. [More]
Study demonstrates that activation of cannabinoid CB2 receptors suppresses chronic pain

Study demonstrates that activation of cannabinoid CB2 receptors suppresses chronic pain

Medical marijuana is proliferating across the country due to the ability of cannabis ingestion to treat important clinical problems such as chronic pain. However, negative side effects and the development of tolerance limit the widespread therapeutic use of Δ9-tetrahydrocannabinol (Δ9-THC), the major psychoactive ingredient in cannabis. [More]
FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

FDA grants Orphan Drug Designation to Oncolytics' REOLYSIN for treatment of peritoneal cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of primary peritoneal cancers. [More]
Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Oncolytics' REOLYSIN granted FDA Orphan Drug Designation for treatment of fallopian tube cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of cancer of the fallopian tube. [More]
Researchers develop revolutionary approach to treat drug-resistant tumors

Researchers develop revolutionary approach to treat drug-resistant tumors

In greater than 90 percent of cases in which treatment for metastatic cancer fails, the reason is that the cancer is resistant to the drugs being used. To treat drug-resistant tumors, doctors typically use multiple drugs simultaneously, a practice called combination therapy. [More]
Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib extends progression-free survival in advanced breast cancer patients

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments. [More]
Oncolytics' REOLYSIN receives FDA Orphan Drug Designation for treatment of ovarian cancer

Oncolytics' REOLYSIN receives FDA Orphan Drug Designation for treatment of ovarian cancer

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of ovarian cancer. [More]
Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Historic five-year results from the world’s largest clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) were presented last week at the Leipzig Interventional Course, in Germany. The data confirm long-term patency for patients treated with Zilver® PTX®. [More]
Scientists identify first genetic marker linked to severe neurological toxicity

Scientists identify first genetic marker linked to severe neurological toxicity

Paclitaxel is a chemotherapeutic drug that has been shown to be highly effective when treating solid tumours, such as breast, ovarian and lung tumours. However, its use frequently causes peripheral neuropathies, neurological problems that affect the vast majority of patients. [More]
Combination therapy can reduce recurrence of small, HER2-positive breast tumors

Combination therapy can reduce recurrence of small, HER2-positive breast tumors

In a phase 2 clinical trial, women with small (stage 1), HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine. [More]
Lilly receives FDA approval for CYRAMZA (ramucirumab)

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). [More]
Carboplatin and paclitaxel show promise for advanced thymic carcinoma

Carboplatin and paclitaxel show promise for advanced thymic carcinoma

A multicentre, phase II study of carboplatin and paclitaxel in chemotherapy-naïve patients with advanced thymic carcinoma has shown that the treatment has promising efficacy compared with standard anthracycline-based chemotherapy. [More]
Johns Hopkins researchers discover new way to treat triple-negative breast cancer

Johns Hopkins researchers discover new way to treat triple-negative breast cancer

Triple-negative breast cancer is as bad as it sounds. The cells that form these tumors lack three proteins that would make the cancer respond to powerful, customized treatments. Instead, doctors are left with treating these patients with traditional chemotherapy drugs that only show long-term effectiveness in 20 percent of women with triple-negative breast cancer. [More]
Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13. [More]
FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. [More]

Experimental drug may help fight cervical cancer

University of Leicester academic leads study into effects of cediranib drug in chemotherapy treatment of cervical cancer. [More]
New study reveals how cancer becomes drug resistant over time

New study reveals how cancer becomes drug resistant over time

Like a colony of bacteria or species of animals, cancer cells within a tumor must evolve to survive. A dose of chemotherapy may kill hundreds of thousands of cancer cells, for example, but a single cell with a unique mutation can survive and quickly generate a new batch of drug-resistant cells, making cancer hard to combat. [More]
Mount Sinai Hospital first in nation to use drug-coated balloon to open blocked arteries in the leg

Mount Sinai Hospital first in nation to use drug-coated balloon to open blocked arteries in the leg

The Mount Sinai Hospital is first in the United States to use the first and only FDA-approved, drug-coated balloon to open blocked arteries in the leg. [More]
Advertisement
Advertisement